Protagonist Therapeutics (NASDAQ:PTGX) Given “Outperform” Rating at Wedbush
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report)‘s stock had its “outperform” rating reiterated by stock analysts at Wedbush in a research note issued to investors on Friday,RTT News reports. They currently have a $58.00 price target on the stock. Wedbush’s target price indicates a potential upside of 49.68% from the company’s current price. A number […]
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report)‘s stock had its “outperform” rating reiterated by stock analysts at Wedbush in a research note issued to investors on Friday,RTT News reports. They currently have a $58.00 price target on the stock. Wedbush’s target price indicates a potential upside of 49.68% from the company’s current price. A number […]
